Gastrointestinal Imaging

Hepatobiliary and Pancreatic Neoplasms: Essential Predictive Imaging Features for Personalized Therapy

Published Online:Feb 6 2025https://doi.org/10.1148/rg.240068

See the invited commentary by Ronot in this issue.

Abstract

Predictive radiologic imaging combined with a clear understanding of tumor biologic characteristics aids in tailoring treatment plans for individuals with hepatobiliary and pancreatic neoplasms, and radiologists must grasp the implications of these findings to improve patient outcomes.

Tumor biologic characteristics encompassing histopathologic, immune microenvironmental, genetic, and molecular aspects are becoming indispensable factors to be considered in treatment strategies for patients with cancer. Innovations in oncologic treatment have broadened the range of therapeutic approaches and now hold promise for treatments personalized according to tumor biologic characteristics. Particularly for hepatobiliary and pancreatic neoplasms, the advent of cytostatic agents such as molecularly targeted agents and immune checkpoint inhibitors, which differ markedly from conventional cytotoxic agents, has contributed to advances in clinical practice. These cytostatic agents increase the potential for curative-intent treatment of unresectable cancers by reducing tumor volume. Radiologic examinations are of more interest than ever to noninvasively obtain information about tumor biologic features. Radiomics represents an invaluable research method for elucidating associations between tumor biologic characteristics and radiologic imaging findings, but their applicability in daily clinical practice remains challenging. Various radiologic predictive findings for tumor biologic characteristics have already been proposed for hepatobiliary and pancreatic neoplasms. Radiologists must gain familiarity with these findings and the roles they have in predicting the clinical prognosis and treatment efficacy. In addition, radiologists should explore the potential applications of these imaging findings to current treatment strategies for the coming era of personalized medicine. The authors describe predictive findings using CT and MRI for diagnosis of hepatocellular carcinoma, colorectal liver metastases, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma, with correlations to pathologic, immunologic, molecular, and genetic background factors.

^©RSNA, 2025

Supplemental material is available for this article.

See the invited commentary by Ronot in this issue.

References

1. Lencioni R, Kudo M, Erinjeri J, Quin S. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. J Clin Oncol 2024;42(3_suppl):LBA432–LBA432.
Google Scholar
2. Montironi C, Castet F, Haber PK, et al. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut 2023;72(1):129–140.
Medline Google Scholar
3. Li M, Yin Z, Hu B, et al. MR Elastography-Based Shear Strain Mapping for Assessment of Microvascular Invasion in Hepatocellular Carcinoma. Eur Radiol 2022;32(7):5024–5032.
Medline Google Scholar
4. Ronot M, Chernyak V, Burgoyne A, et al. Imaging to Predict Prognosis in Hepatocellular Carcinoma: Current and Future Perspectives. Radiology 2023;307(3):e221429.
Google Scholar
5. Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020;382(20):1894–1905.
Medline Google Scholar
6. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evid 2022;1(8):a2100070.
Google Scholar
7. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76(3):681–693.
Medline Google Scholar
8. Montironi C, Castet F, Haber PK, et al. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut 2023;72(1):129–140.
Medline Google Scholar
9. Renne SL, Sarcognato S, Sacchi D, et al. Hepatocellular carcinoma: a clinical and pathological overview. Pathologica 2021;113(3):203–217.
Medline Google Scholar
10. Ahn SY, Lee JM, Joo I, et al. Prediction of microvascular invasion of hepatocellular carcinoma using gadoxetic acid-enhanced MR and (18)F-FDG PET/CT. Abdom Imaging 2015;40(4):843–851.
Medline Google Scholar
11. Wang X, Chen D, Chen B. The Long-To-Short-Axis Ratio and Multifocality are Associated With TP53 Mutation Status in Surgically Resected Hepatocellular Carcinomas. Acad Radiol 2020;27(12):1720–1726.
Medline Google Scholar
12. An C, Choi GH, Lee HS, Kim MJ. Assessment of preoperative magnetic resonance imaging staging in patients with hepatocellular carcinoma undergoing resection compared with the seventh American Joint Committee on Cancer System. Invest Radiol 2012;47(11):634–641.
Medline Google Scholar
13. Wei H, Jiang H, Liu X, et al. Can LI-RADS imaging features at gadoxetic acid-enhanced MRI predict aggressive features on pathology of single hepatocellular carcinoma? Eur J Radiol 2020;132:109312.
Medline Google Scholar
14. Lu DS, Siripongsakun S, Kyong Lee J, et al. Complete tumor encapsulation on magnetic resonance imaging: a potentially useful imaging biomarker for better survival in solitary large hepatocellular carcinoma. Liver Transpl 2013;19(3):283–291.
Medline Google Scholar
15. Inui S, Kondo H, Tanahashi Y, et al. Steatohepatitic hepatocellular carcinoma: imaging findings with clinicopathological correlation. Clin Radiol 2021;76(2):160.e15–160.e25.
Medline Google Scholar
16. Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M. Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 2000;33(2):282–289.
Medline Google Scholar
17. Asayama Y, Nishie A, Ishigami K, et al. Fatty change in moderately and poorly differentiated hepatocellular carcinoma on MRI: a possible mechanism related to decreased arterial flow. Clin Radiol 2016;71(12):1277–1283.
Medline Google Scholar
18. Murai H, Kodama T, Maesaka K, et al. Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma. Hepatology 2023;77(1):77–91.
Medline Google Scholar
19. Siripongsakun S, Lee JK, Raman SS, Tong MJ, Sayre J, Lu DS. MRI detection of intratumoral fat in hepatocellular carcinoma: potential biomarker for a more favorable prognosis. AJR Am J Roentgenol 2012;199(5):1018–1025.
Medline Google Scholar
20. Surov A, Pech M, Omari J, et al. Diffusion-Weighted Imaging Reflects Tumor Grading and Microvascular Invasion in Hepatocellular Carcinoma. Liver Cancer 2021;10(1):10–24.
Medline Google Scholar
21. Chuang YH, Ou HY, Yu CY, et al. Diffusion-weighted imaging for identifying patients at high risk of tumor recurrence following liver transplantation. Cancer Imaging 2019;19(1):74.
Medline Google Scholar
22. Mori Y, Tamai H, Shingaki N, et al. Signal intensity of small hepatocellular carcinoma on apparent diffusion coefficient mapping and outcome after radiofrequency ablation. Hepatol Res 2015;45(1):75–87.
Medline Google Scholar
23. Kang HJ, Kim H, Lee DH, et al. Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology 2021;300(3):572–582.
Google Scholar
24. Rhee H, An C, Kim HY, Yoo JE, Park YN, Kim MJ. Hepatocellular carcinoma with irregular rim-like arterial phase hyperenhancement: more aggressive pathologic features. Liver Cancer 2019;8(1):24–40.
Medline Google Scholar
25. Zhou L, Zhu Y. The EpCAM overexpression is associated with clinicopathological significance and prognosis in hepatocellular carcinoma patients: A systematic review and meta-analysis. Int J Surg 2018;56:274–280.
Medline Google Scholar
26. Choi SY, Kim SH, Park CK, et al. Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study. Radiology 2018;286(3):897–908.
Google Scholar
27. Kawamura Y, Ikeda K, Seko Y, et al. Heterogeneous type 4 enhancement of hepatocellular carcinoma on dynamic CT is associated with tumor recurrence after radiofrequency ablation. AJR Am J Roentgenol 2011;197(4):W665–W673.
Medline Google Scholar
28. Kitao A, Matsui O, Zhang Y, et al. Dynamic CT and Gadoxetic Acid-enhanced MRI Characteristics of P53-mutated Hepatocellular Carcinoma. Radiology 2023;306(2):e220531.
Google Scholar
29. Rodríguez-Hernández MA, Chapresto-Garzón R, Cadenas M, et al. Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells. Cell Death Dis 2020;11(5):339.
Medline Google Scholar
30. Wei H, Jiang H, Zheng T, et al. LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MRI for early recurrence risk stratification after curative resection. Eur Radiol 2021;31(4):2289–2302.
Medline Google Scholar
31. Sun L, Mu L, Zhou J, et al. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother 2022;71(1):25–38.
Medline Google Scholar
32. Kang TW, Rhim H, Lee J, et al. Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma. Eur Radiol 2016;26(10):3437–3446.
Medline Google Scholar
33. Ueno A, Masugi Y, Yamazaki K, et al. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol 2014;61(5):1080–1087.
Medline Google Scholar
34. Kitao A, Matsui O, Yoneda N, et al. Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology 2012;265(3):780–789.
Google Scholar
35. Kudo M. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer 2020;9(5):479–490.
Medline Google Scholar
36. Ishimaru H, Nakashima K, Sakugawa T, et al. Local recurrence after chemoembolization of hepatocellular carcinoma: uptake of gadoxetic acid as a new prognostic factor. AJR Am J Roentgenol 2014;202(4):744–751.
Medline Google Scholar
37. Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA, Sparreboom A. Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther 2013;12(8):1537–1544.
Medline Google Scholar
38. Sasaki R, Nagata K, Fukushima M, et al. Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2022;14(3):827.
Medline Google Scholar
39. Fujita N, Nishie A, Kubo Y, et al. Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging. Eur Radiol 2015;25(1):211–220.
Medline Google Scholar
40. Minamiguchi K, Nishiofuku H, Saito N, et al. Quantitative Analysis of Signal Heterogeneity in the Hepatobiliary Phase of Pretreatment Gadoxetic Acid-Enhanced MRI as a Prognostic Imaging Biomarker in Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma. Cancers (Basel) 2023;15(4):1238.
Medline Google Scholar
41. Feng M, Zhang M, Liu Y, et al. Texture analysis of MR images to identify the differentiated degree in hepatocellular carcinoma: a retrospective study. BMC Cancer 2020;20(1):611.
Medline Google Scholar
42. Hectors SJ, Wagner M, Bane O, et al. Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. Sci Rep 2017;7(1):2452.
Medline Google Scholar
43. Lee JY, Lee BC, Kim HO, Heo SH, Shin SS, Jeong YY. Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma. Sci Rep 2021;11(1):24076.
Medline Google Scholar
44. Kaibori M, Sakai K, Matsushima H, et al. Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period. Hepatol Int 2022;16(1):135–147.
Medline Google Scholar
45. Choi SH, Lee SS, Park SH, et al. LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid-enhanced MRI. Radiology 2019;290(2):388–397.
Google Scholar
46. Cannella R, Matteini F, Dioguardi Burgio M, et al. Association of LI-RADS and Histopathologic Features with Survival in Patients with Solitary Resected Hepatocellular Carcinoma. Radiology 2024;310(2):e231160.
Google Scholar
47. van Dam PJ, van der Stok EP, Teuwen LA, et al. International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. Br J Cancer 2017;117(10):1427–1441.
Medline Google Scholar
48. Li WH, Wang S, Liu Y, Wang XF, Wang YF, Chai RM. Differentiation of histopathological growth patterns of colorectal liver metastases by MRI features. Quant Imaging Med Surg 2022;12(1):608–617.
Medline Google Scholar
49. Cheng J, Qiu M, Zhang Y, et al. Enhanced Rim on MDCT of Colorectal Liver Metastases: Assessment of Ability to Predict Progression-Free Survival and Response to Bevacizumab-Based Chemotherapy. AJR Am J Roentgenol 2020;215(6):1377–1383.
Medline Google Scholar
50. Frentzas S, Simoneau E, Bridgeman VL, et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med 2016;22(11):1294–1302.
Medline Google Scholar
51. Reynolds IS, Cromwell PM, Hoti E. Clinicopathological characteristics and survival outcomes for patients with mucinous colorectal cancer liver metastases undergoing hepatic resection: A systematic review and meta-analysis. Am J Surg 2021;222(3):529–535.
Medline Google Scholar
52. Zhou Y, Zhang J, Dan Pu, et al. Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer. Anticancer Drugs 2019;30(2):195–200.
Medline Google Scholar
53. Cheung HMC, Karanicolas PJ, Coburn N, Seth V, Law C, Milot L. Delayed tumour enhancement on gadoxetate-enhanced MRI is associated with overall survival in patients with colorectal liver metastases. Eur Radiol 2019;29(2):1032–1038.
Medline Google Scholar
54. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007;18(2):299–304.
Medline Google Scholar
55. Wang X, Wang Y, Zhang Z, et al. Rim enhancement on hepatobiliary phase of pre-treatment 3.0 T MRI: A potential marker for early chemotherapy response in colorectal liver metastases treated with XELOX. Eur J Radiol 2021;143:109887 [Published correction appears in Eur J Radiol 2022;148:110154.].
Medline Google Scholar
56. Park SH, Kim H, Kim EK, et al. Aberrant expression of OATP1B3 in colorectal cancer liver metastases and its clinical implication on gadoxetic acid-enhanced MRI. Oncotarget 2017;8(41):71012–71023.
Medline Google Scholar
57. Murata S, Matsushima S, Sato Y, et al. Predicting chemotherapeutic response for colorectal liver metastases using relative tumor enhancement of gadoxetic acid disodium-enhanced magnetic resonance imaging. Abdom Radiol (NY) 2018;43(12):3301–3306.
Medline Google Scholar
58. Oh DY, He AR, Qin S, et al. Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer. Future Oncol 2023;19(34):2277–2289 [Published correction appears in Future Oncol 2024;20(6):349.].
Medline Google Scholar
59. Makawita S, K Abou-Alfa G, Roychowdhury S, et al. Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol 2020;16(30):2375–2384.
Medline Google Scholar
60. Hayashi A, Misumi K, Shibahara J, et al. Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma. Am J Surg Pathol 2016;40(8):1021–1030.
Medline Google Scholar
61. Pandey A, Pandey P, Ghasabeh MA, et al. Baseline Volumetric Multiparametric MRI: Can It Be Used to Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma Undergoing Transcatheter Arterial Chemoembolization? Radiology 2018;289(3):843–853.
Google Scholar
62. Pandey A, Mohseni A, Shaghaghi M, et al. Incremental value of volumetric multiparametric MRI over Fudan score for prognosis of unresectable intrahepatic cholangiocarcinoma treated with systemic chemotherapy. Eur J Radiol 2024;170:111196.
Medline Google Scholar
63. Fujita N, Asayama Y, Nishie A, et al. Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings. Eur Radiol 2017;27(2):498–506.
Medline Google Scholar
64. Panettieri E, Maki H, Kim BJ, et al. Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. Surg Oncol 2022;40:101696.
Medline Google Scholar
65. Asayama Y, Yoshimitsu K, Irie H, et al. Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology 2006;238(1):150–155.
Google Scholar
66. Koh J, Chung YE, Nahm JH, et al. Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI. Eur Radiol 2016;26(2):407–416.
Medline Google Scholar
67. Belfiori G, Crippa S, Francesca A, et al. Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival. Ann Surg Oncol 2021;28(13):8249–8260.
Medline Google Scholar
68. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19(4):439–457.
Medline Google Scholar
69. Kim JH, Park SH, Yu ES, et al. Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology 2010;257(1):87–96.
Google Scholar
70. Liang H, Zhou Y, Zheng Q, et al. Dual-energy CT with virtual monoenergetic images and iodine maps improves tumor conspicuity in patients with pancreatic ductal adenocarcinoma. Insights Imaging 2022;13(1):153.
Medline Google Scholar
71. Yoon SH, Lee JM, Cho JY, et al. Small (≤ 20 mm) pancreatic adenocarcinomas: analysis of enhancement patterns and secondary signs with multiphasic multidetector CT. Radiology 2011;259(2):442–452.
Google Scholar
72. Lee S, Kim SH, Park HK, Jang KT, Hwang JA, Kim S. Pancreatic Ductal Adenocarcinoma: Rim Enhancement at MR Imaging Predicts Prognosis after Curative Resection. Radiology 2018;288(2):456–466.
Google Scholar
73. Leppänen J, Helminen O, Huhta H, et al. Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma. World J Surg Oncol 2018;16(1):127.
Medline Google Scholar
74. Kim H, Kim DH, Song IH, et al. Identification of intratumoral fluid-containing area by magnetic resonance imaging to predict prognosis in patients with pancreatic ductal adenocarcinoma after curative resection. Eur Radiol 2022;32(4):2518–2528.
Medline Google Scholar
75. Choi SJ, Kim SJ, Kim DW, et al. Large Duct Pancreatic Ductal Adenocarcinoma: A Morphological Variant of Pancreatic Ductal Adenocarcinoma With Distinct CT and MRI Characteristics. Korean J Radiol 2023;24(12):1232–1240.
Medline Google Scholar
76. Hayano K, Miura F, Amano H, et al. Correlation of apparent diffusion coefficient measured by diffusion-weighted MRI and clinicopathologic features in pancreatic cancer patients. J Hepatobiliary Pancreat Sci 2013;20(2):243–248.
Medline Google Scholar
77. Garces-Descovich A, Morrison TC, Beker K, Jaramillo-Cardoso A, Moser AJ, Mortele KJ. DWI of Pancreatic Ductal Adenocarcinoma: A Pilot Study to Estimate the Correlation With Metastatic Disease Potential and Overall Survival. AJR Am J Roentgenol 2019;212(2):323–331.
Medline Google Scholar
78. Niwa T, Ueno M, Ohkawa S, et al. Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapy. Br J Radiol 2009;82(973):28–34.
Medline Google Scholar
79. Erkan M, Michalski CW, Rieder S, et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 2008;6(10):1155–1161.
Medline Google Scholar
80. Fukukura Y, Kumagae Y, Higashi R, et al. Visual enhancement pattern during the delayed phase of enhanced CT as an independent prognostic factor in stage IV pancreatic ductal adenocarcinoma. Pancreatology 2020;20(6):1155–1163.
Medline Google Scholar
81. Wang ZJ, Zhang TT, An C, et al. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol 2020;215(3):610–616.
Medline Google Scholar

Article History

Received: Mar 19 2024
Revision requested: Apr 15 2024
Revision received: May 21 2024
Accepted: May 30 2024
Published online: Feb 06 2025

Vol. 45, No. 3

Test Your Knowledge

Supplemental Material

Abbreviations

Abbreviations:
ADC	apparent diffusion coefficient
CRLM	colorectal liver metastases
HBP	hepatobiliary phase
HCC	hepatocellular carcinoma
ICC	intrahepatic cholangiocarcinoma
LI-RADS	Liver Imaging Reporting and Data System
PDAC	pancreatic ductal adenocarcinoma

Metrics

Altmetric Score

PDF download